Search

Displaying results 6001 - 6010 of 8697 in total
  1. Drug

    Vestipitant

    go.drugbank.com/drugs/DB11949
    Investigational

    Vestipitant has been investigated for the treatment of Tinnitus.

    Categories: Neurokinin-1 Receptor Antagonists
  2. Drug

    GW-870086

    go.drugbank.com/drugs/DB12322
    Investigational

    GW870086X has been investigated for the treatment of ASTHMA.

  3. Drug

    Ipamorelin

    go.drugbank.com/drugs/DB12370
    Investigational

    Ipamorelin has been investigated for the treatment of Ileus.

  4. Drug

    Modufolin

    go.drugbank.com/drugs/DB12676
    Investigational

    Modufolin is under investigation for the treatment of Osteosarcoma.

  5. Drug

    Enecadin

    go.drugbank.com/drugs/DB13032
    Investigational

    Enecadin has been investigated for the treatment of Stroke.

  6. Drug

    Cyclo(prolylglycyl)

    go.drugbank.com/drugs/DB04541
    Investigational

    with Atazanavir and Dexamethasone for COVID-19). … NA-831 (Traneurocin), is under investigation in two clinical trials: NCT03538522 (completed, for mild cognitive impairment and Alzheimer’s disease) and NCT04452565 (unknown status, combination therapy

  7. Drug

    Amobarbital

    go.drugbank.com/drugs/DB01351
    ApprovedIllicit

    A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmac...

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  8. Drug

    XL281

    go.drugbank.com/drugs/DB05190
    Investigational

    XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon ca...

  9. Drug

    Acadesine

    go.drugbank.com/drugs/DB04944
    Investigational

    Acadesine has been granted Orphan Drug Designation for B-CLL in the EU. … Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing

  10. Drug

    L523S

    go.drugbank.com/drugs/DB06498
    Investigational

    According to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S) … and when delivered following incorporation into an E1B-deleted adenovirus (Ad/L523S)."